Generic Products (March 2019)

MARCH 09, 2019















ALBENDAZOLE TABLETS
MARKETED BY: Camber Pharmaceuticals
COMPARE TO: Albenza
Camber Pharmaceuticals recently announced the approval of Albendazole Tablets, its generic version of Albenza, to treat parasite and tapeworm infections. The tablets are available by prescription, with 2 doses of the 200-mg pills to treat the infection. Albendazole can treat 2 different conditions, hydatid and neurocysticercosis, both of which are caused by tapeworm larvae.
DOSAGE FORM: Tablets
FOR MORE INFORMATION: camberpharma.com





WIXELA INHUB 
MARKETED BY: Mylan NV
COMPARE TO: Advair Diskus
The FDA recently approved Mylan’s Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP). The drug is the first FDA approved generic of Advair Diskus, a treatment for asthma and chronic obstructive pulmonary disease (COPD). Wixela Inhub can be used twice daily by patients 4 years and older with asthma that is not being adequately controlled in the long term by patients with asthma who require both inhaled corticosteroids and long-acting beta antagonists for maintenance, for COPD maintenance, and for the reduction of COPD exacerbations.
DOSAGE FORM: Inhalation powder
FOR MORE INFORMATION: mylan.com


















DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE EXTENDED-RELEASE TABLETS
MARKETED BY: Amerigen
COMPARE TO: Adderall XR Amerigen has received FDA approval for its mixed amphetamine salts dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release tablets. The drug is indicated for the treatment of attention deficit hyperactivity disorder in patients older than 6 years.
DOSAGE FORM: Extended-release capsule
FOR MORE INFORMATION: amerigenpharma.com













VIGABATRIN 
MARKETED BY: Teva Pharmaceuticals
COMPARE TO: Sabril
Vigabatrin has been approved as a generic equivalent to Sabril as an adjunctive treatment for patients older than 10 years with refractory complex partial seizures who have not responded well to alternative treatments. The drug is not recommended as a first-line treatment, and the risks should be thoroughly assessed and compared with the benefits before starting treatment, as vigabatrin has serious risks, including vision loss.
DOSAGE FORM: Oral tablets
FOR MORE INFORMATION: tevapharm.com

SHARE THIS
0